Trial Profile
An Open Label, Dose Escalation Followed by Dose Expansion, Safety and Tolerability Trial of CAN04, a Fully Humanized Monoclonal Antibody Against IL1RAP, in Subjects With Solid Malignant Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 29 Mar 2024
Price :
$35
*
At a glance
- Drugs Nadunolimab (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel; Pemetrexed
- Indications Adenocarcinoma; Advanced breast cancer; Colorectal cancer; Male breast cancer; Non-small cell lung cancer; Pancreatic cancer; Squamous cell cancer; Triple negative breast cancer
- Focus Adverse reactions; First in man
- Acronyms CANFOUR
- Sponsors Cantargia
- 29 Mar 2024 This trial has been completed in Lithuania, according to European Clinical Trials Database record.
- 27 Mar 2024 This trial has been completed in Belgium (Global end date: 14 March 2024).
- 16 Oct 2023 Planned End Date changed from 1 Oct 2022 to 31 Dec 2023.